SG165416A1 - Chemical process - Google Patents

Chemical process

Info

Publication number: SG165416A1
Authority: SG; Singapore
Prior art keywords: manufacture; processes; relates; quinazoline derivatives; quinazoline
Prior art date: 2005-09-30

Application number

SG201006940-9A

Other languages

English (en)

Inventor

Joergen Blixt

Michael David Golden

Philip John Hogan

David Michael Glanville Martin

Francis Joseph Montgomery

Zakariya Patel

John David Pittam

George Joseph Sependa

Christopher John Squire

Nicholas Cartwright Alexander Wright

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-30

Filing date

2006-09-27

Publication date

2010-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG165416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-27 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2010-10-28 Publication of SG165416A1 publication Critical patent/SG165416A1/en

Links

238000001311 chemical methods and process Methods 0.000 title abstract 3
238000004519 manufacturing process Methods 0.000 abstract 5
239000000543 intermediate Substances 0.000 abstract 3
150000003246 quinazolines Chemical class 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SG201006940-9A 2005-09-30 2006-09-27 Chemical process SG165416A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0519879.1A GB0519879D0 (en)	2005-09-30	2005-09-30	Chemical process

Publications (1)

Publication Number	Publication Date
SG165416A1 true SG165416A1 (en)	2010-10-28

Family

ID=35395001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201006940-9A SG165416A1 (en)	2005-09-30	2006-09-27	Chemical process

Country Status (31)

Country	Link
US (8)	US8163926B2 (de)
EP (2)	EP1943240B1 (de)
JP (2)	JP5213715B2 (de)
KR (1)	KR101307641B1 (de)
CN (3)	CN102503933B (de)
AR (1)	AR055671A1 (de)
AT (2)	ATE481399T1 (de)
AU (1)	AU2006296367B2 (de)
BR (1)	BRPI0616715A2 (de)
CA (2)	CA2745829C (de)
CY (2)	CY1110275T1 (de)
DE (2)	DE602006010428D1 (de)
DK (2)	DK2053048T3 (de)
ES (2)	ES2335435T3 (de)
GB (1)	GB0519879D0 (de)
HR (2)	HRP20100019T1 (de)
IL (2)	IL190172A (de)
ME (2)	ME01466B (de)
MY (2)	MY145540A (de)
NO (1)	NO342152B1 (de)
NZ (2)	NZ566566A (de)
PL (2)	PL2053048T3 (de)
PT (2)	PT1943240E (de)
RS (2)	RS51263B (de)
RU (1)	RU2448102C2 (de)
SG (1)	SG165416A1 (de)
SI (2)	SI1943240T1 (de)
TW (2)	TWI424991B (de)
UY (1)	UY29824A1 (de)
WO (1)	WO2007036713A2 (de)
ZA (1)	ZA200802416B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI1474420T1 (sl) *	2002-02-01	2012-06-29	Astrazeneca Ab	Spojine kinazolina
GB0519879D0 (en) *	2005-09-30	2005-11-09	Astrazeneca Ab	Chemical process
CL2007003158A1 (es) *	2006-11-02	2008-05-16	Astrazeneca Ab	Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP2404595B1 (de) *	2011-09-01	2015-08-05	Symrise AG	Verfahren zur Herstellung von Indanon-Derivaten
BR112015003101B1 (pt) *	2012-08-15	2022-06-14	Glaxo Group Limited	Processo para a preparação de um composto
CN104098544A (zh) *	2013-04-07	2014-10-15	浙江九洲药物科技有限公司	一种凡德他尼的制备方法
CN106397401B (zh) *	2016-08-30	2018-11-13	山东罗欣药业集团股份有限公司	一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4870083A (en)	1987-11-24	1989-09-26	Merrell Dow Pharmaceuticals Inc.	1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja)	1989-05-31	1998-12-02	川研ファインケミカル株式会社	ピペリジンカルボン酸類の製造方法
AU8506791A (en)	1990-10-01	1992-04-28	Janssen Pharmaceutica N.V.	Novel 4-piperidinylcarbonyl derivatives
HU225047B1 (en)	1991-03-28	2006-05-29	Eisai Co Ltd	Heterocyclic-piperidin-derivatives, pharmaceutical compositions containing them and process for their production
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en)	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5624926A (en)	1993-02-18	1997-04-29	Kyowa Hakko Kogyo Co., Ltd.	Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
AU680004B2 (en) *	1993-05-26	1997-07-17	Syntex (U.S.A.) Inc.	Novel 1-phenylalkanone 5-HT4 receptor ligands
DE4326344A1 (de)	1993-08-05	1995-02-09	Thomae Gmbh Dr K	Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ES2120170T3 (es) *	1994-01-13	1998-10-16	Merck Sharp & Dohme	Antagonistas azaciclicos gem-disustituidos de taquiquininas.
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0954315A2 (de)	1996-09-13	1999-11-10	Sugen, Inc.	Verwendung von quinazolinderivate zur herstellung eines arzneimittels zur behandlung hyperproliferativer hautkrankheiten
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
KR100881105B1 (ko) *	1999-11-05	2009-02-02	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
EA012926B1 (ru)	2001-12-20	2010-02-26	Оси Фармасьютикалз, Инк.	Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
SI1474420T1 (sl)	2002-02-01	2012-06-29	Astrazeneca Ab	Spojine kinazolina
WO2003066602A1 (en)	2002-02-06	2003-08-14	Ube Industries, Ltd.	Process for producing 4-aminoquinazoline compound
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
AU2003249000B2 (en)	2002-08-09	2007-04-05	Astrazeneca Ab	Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
KR20050100683A (ko)	2003-02-13	2005-10-19	아스트라제네카 아베	5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (de)	2003-07-10	2010-08-25	AstraZeneca AB	Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
GB0318423D0 (en)	2003-08-06	2003-09-10	Astrazeneca Ab	Chemical compounds
GB0519879D0 (en) *	2005-09-30	2005-11-09	Astrazeneca Ab	Chemical process

2005
- 2005-09-30 GB GBGB0519879.1A patent/GB0519879D0/en not_active Ceased
2006
- 2006-09-27 AU AU2006296367A patent/AU2006296367B2/en not_active Ceased
- 2006-09-27 DE DE602006010428T patent/DE602006010428D1/de active Active
- 2006-09-27 NZ NZ566566A patent/NZ566566A/en not_active IP Right Cessation
- 2006-09-27 PL PL09152654T patent/PL2053048T3/pl unknown
- 2006-09-27 CA CA2745829A patent/CA2745829C/en not_active Expired - Fee Related
- 2006-09-27 WO PCT/GB2006/003587 patent/WO2007036713A2/en not_active Ceased
- 2006-09-27 MY MYPI20080855A patent/MY145540A/en unknown
- 2006-09-27 HR HR20100019T patent/HRP20100019T1/hr unknown
- 2006-09-27 RS RSP-2010/0037A patent/RS51263B/sr unknown
- 2006-09-27 SG SG201006940-9A patent/SG165416A1/en unknown
- 2006-09-27 KR KR1020087009317A patent/KR101307641B1/ko not_active Expired - Fee Related
- 2006-09-27 CA CA2624045A patent/CA2624045C/en not_active Expired - Fee Related
- 2006-09-27 MY MYPI2011003076A patent/MY149834A/en unknown
- 2006-09-27 EP EP06794582A patent/EP1943240B1/de active Active
- 2006-09-27 PL PL06794582T patent/PL1943240T3/pl unknown
- 2006-09-27 EP EP09152654A patent/EP2053048B8/de active Active
- 2006-09-27 CN CN201110159628.2A patent/CN102503933B/zh active Active
- 2006-09-27 SI SI200630524T patent/SI1943240T1/sl unknown
- 2006-09-27 AT AT09152654T patent/ATE481399T1/de active
- 2006-09-27 RS RSP-2010/0520A patent/RS51515B/sr unknown
- 2006-09-27 DK DK09152654.1T patent/DK2053048T3/da active
- 2006-09-27 PT PT06794582T patent/PT1943240E/pt unknown
- 2006-09-27 ES ES06794582T patent/ES2335435T3/es active Active
- 2006-09-27 CN CN200680036468XA patent/CN101277948B/zh active Active
- 2006-09-27 NZ NZ593930A patent/NZ593930A/xx not_active IP Right Cessation
- 2006-09-27 DE DE602006017004T patent/DE602006017004D1/de active Active
- 2006-09-27 ES ES09152654T patent/ES2350513T3/es active Active
- 2006-09-27 PT PT09152654T patent/PT2053048E/pt unknown
- 2006-09-27 AT AT06794582T patent/ATE448218T1/de active
- 2006-09-27 JP JP2008532864A patent/JP5213715B2/ja not_active Expired - Fee Related
- 2006-09-27 CN CN201110159729.XA patent/CN102503898B/zh active Active
- 2006-09-27 ME MEP-2013-21A patent/ME01466B/me unknown
- 2006-09-27 BR BRPI0616715-2A patent/BRPI0616715A2/pt not_active IP Right Cessation
- 2006-09-27 DK DK06794582.4T patent/DK1943240T3/da active
- 2006-09-27 ME MEP-2013-51A patent/ME01531B/me unknown
- 2006-09-27 SI SI200630816T patent/SI2053048T1/sl unknown
- 2006-09-27 US US12/088,680 patent/US8163926B2/en active Active
- 2006-09-27 RU RU2008116573/04A patent/RU2448102C2/ru not_active IP Right Cessation
- 2006-09-29 UY UY29824A patent/UY29824A1/es unknown
- 2006-09-29 TW TW099102690A patent/TWI424991B/zh not_active IP Right Cessation
- 2006-09-29 TW TW095136340A patent/TWI328580B/zh not_active IP Right Cessation
- 2006-09-29 AR ARP060104320A patent/AR055671A1/es not_active Application Discontinuation
2008
- 2008-03-11 NO NO20081267A patent/NO342152B1/no not_active IP Right Cessation
- 2008-03-13 IL IL190172A patent/IL190172A/en not_active IP Right Cessation
- 2008-03-14 ZA ZA200802416A patent/ZA200802416B/xx unknown
2010
- 2010-01-25 CY CY20101100076T patent/CY1110275T1/el unknown
- 2010-11-12 CY CY20101101019T patent/CY1110887T1/el unknown
- 2010-11-16 HR HR20100620T patent/HRP20100620T1/hr unknown
2011
- 2011-12-07 US US13/314,034 patent/US8865899B2/en active Active
2012
- 2012-11-28 JP JP2012259782A patent/JP5654546B2/ja not_active Expired - Fee Related
2013
- 2013-07-21 IL IL227574A patent/IL227574A/en not_active IP Right Cessation
2014
- 2014-09-09 US US14/481,302 patent/US20140378684A1/en not_active Abandoned
2015
- 2015-07-22 US US14/805,816 patent/US9815816B2/en active Active
2017
- 2017-10-27 US US15/796,615 patent/US10344015B2/en active Active
2019
- 2019-05-08 US US16/406,246 patent/US20190263782A1/en not_active Abandoned
2020
- 2020-11-02 US US17/086,666 patent/US20220033377A1/en not_active Abandoned
2023
- 2023-03-07 US US18/118,549 patent/US20240150317A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE481399T1 (de)	2010-10-15
ATE448218T1 (de)	2009-11-15
US20160185754A1 (en)	2016-06-30
US20180118716A1 (en)	2018-05-03
US20220033377A1 (en)	2022-02-03
DK1943240T3 (da)	2010-03-01
US20190263782A1 (en)	2019-08-29
CN101277948B (zh)	2013-03-13
CN102503933B (zh)	2014-06-25
AU2006296367B2 (en)	2011-08-11
KR101307641B1 (ko)	2013-09-12
TWI424991B (zh)	2014-02-01
JP2013063998A (ja)	2013-04-11
TW200745036A (en)	2007-12-16
MY145540A (en)	2012-02-29
NZ566566A (en)	2011-08-26
IL190172A0 (en)	2008-08-07
CA2624045C (en)	2012-05-22
BRPI0616715A2 (pt)	2011-06-28
US20140378684A1 (en)	2014-12-25
RU2008116573A (ru)	2009-11-10
NZ593930A (en)	2013-02-22
PT2053048E (pt)	2010-11-10
NO20081267L (no)	2008-04-30
SI1943240T1 (sl)	2010-02-26
EP2053048A1 (de)	2009-04-29
CA2745829C (en)	2013-07-02
CY1110887T1 (el)	2015-06-10
CN102503898A (zh)	2012-06-20
JP5213715B2 (ja)	2013-06-19
IL227574A (en)	2015-08-31
GB0519879D0 (en)	2005-11-09
DE602006010428D1 (de)	2009-12-24
JP2009510039A (ja)	2009-03-12
SI2053048T1 (sl)	2010-12-31
US8163926B2 (en)	2012-04-24
HK1130478A1 (en)	2009-12-31
PL1943240T3 (pl)	2010-04-30
US20090203905A1 (en)	2009-08-13
ES2350513T3 (es)	2011-01-24
AU2006296367A1 (en)	2007-04-05
WO2007036713A3 (en)	2007-06-14
AR055671A1 (es)	2007-08-29
ME01466B (me)	2014-04-20
US8865899B2 (en)	2014-10-21
ES2335435T3 (es)	2010-03-26
JP5654546B2 (ja)	2015-01-14
IL190172A (en)	2014-05-28
CY1110275T1 (el)	2015-01-14
CN102503898B (zh)	2015-03-25
HRP20100620T1 (hr)	2010-12-31
RS51515B (sr)	2011-06-30
CN101277948A (zh)	2008-10-01
EP2053048B1 (de)	2010-09-15
HK1122553A1 (en)	2009-05-22
US10344015B2 (en)	2019-07-09
RU2448102C2 (ru)	2012-04-20
PT1943240E (pt)	2010-01-11
CN102503933A (zh)	2012-06-20
HRP20100019T1 (hr)	2010-02-28
PL2053048T3 (pl)	2011-03-31
DE602006017004D1 (de)	2010-10-28
UY29824A1 (es)	2007-04-30
RS51263B (sr)	2010-12-31
US9815816B2 (en)	2017-11-14
NO342152B1 (no)	2018-04-03
TW201018660A (en)	2010-05-16
CA2745829A1 (en)	2007-04-05
ZA200802416B (en)	2009-01-28
DK2053048T3 (da)	2010-11-29
KR20080049114A (ko)	2008-06-03
EP1943240A2 (de)	2008-07-16
EP1943240B1 (de)	2009-11-11
CA2624045A1 (en)	2007-04-05
US20240150317A1 (en)	2024-05-09
ME01531B (me)	2014-04-20
WO2007036713A2 (en)	2007-04-05
US20120095229A1 (en)	2012-04-19
MY149834A (en)	2013-10-31
TWI328580B (en)	2010-08-11
EP2053048B8 (de)	2011-09-21

Publication	Publication Date	Title
TW200833667A (en)	2008-08-16	Chemical process
ATE447559T1 (de)	2009-11-15	4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
MY159522A (en)	2017-01-13	Administration of dipeptidyl peptidase inhibitors
UA95199C2 (en)	2011-07-11	Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NO20070453L (no)	2007-01-24	Kondenserte heterocykliske kinase inhibitorer
EP1954287A4 (de)	2010-05-05	Cetp-inhibitoren
CL2010000204A1 (es)	2010-12-03	Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
TW200800968A (en)	2008-01-01	Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
ATE457311T1 (de)	2010-02-15	Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
ATE497961T1 (de)	2011-02-15	Als proteinkinaseinhibitoren geeignete verbindungen
CL2011002925A1 (es)	2012-04-13	Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
NZ579928A (en)	2012-09-28	Fluorinated derivatives of deferiprone
CY1116831T1 (el)	2017-03-15	ΧΡΗΣΗ 24-norUDCA
TW200640913A (en)	2006-12-01	5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
CY1110275T1 (el)	2015-01-14	Χημικη διαδικασια
ATE528309T1 (de)	2011-10-15	Als proteinkinaseinhibitoren geeignete verbindungen
EA201001773A1 (ru)	2011-06-30	Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
MX343273B (es)	2016-10-31	Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.
ATE425961T1 (de)	2009-04-15	Salze substituierter allophansaureester und deren verwendung in arzneimitteln
DE602006019830D1 (de)	2011-03-10	Tetrahydro- und dihydrochinazolinone
WO2010068920A3 (en)	2010-09-16	Diaminoquinazoline inhibitors of dihydrofolate reductase
NO20081266L (no)	2008-06-27	4- (4-Brom-2-Fluoranilino) -6-Metoksy-7- (1-Metylpiperidin-4 -Ylmetoksy) kinazolinmonohydrate
TW200637803A (en)	2006-11-01	Processes for the preparation of aminoethoxybenzyl alcohols
TW200640868A (en)	2006-12-01	5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
UA91717C2 (en)	2010-08-25	Administration of 2-[[6-[(3r)-3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo- l(2h)-pyrimaidinyl]methyl]-benzonitrile for the treatment of conditions mediated with dipeptidyl peptidase inhibitors